CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Etanercept +2 moredrug
Likely dose
Etanercept 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00936065
NCT00936065Phase 4Completed
CompareCT.gov

A Multicenter, Randomized, Open Pilot Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly Followed Etanercept 25mg Twice Weekly, the Combination of Etanercept 25 mg Twice Weekly and Acitretin and Acitretin Alone in Patients With Moderate to Severe Psoriasis

Pfizer·interventional·Posted Jul 9, 2009·Updated Apr 9, 2012

In Brief

A Phase 4 clinical trial evaluating Etanercept, Etanercept + Acitretin, and 1 other intervention for Moderate to Severe Psoriasis. Completed, enrolled 60 participants across 10 sites.

Detailed Summary

To compare the efficacy of ETN 50mg twice weekly for 12 weeks followed by reduction to a maintenance dose of 25mg twice weekly at week 24 with that of combination of ETN 25 mg Twice Weekly plus Acitretin 10mg BID at week 24 in subjects with moderate to severe psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Psoriasis
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 9, 2009
Enrollment StartJul 1, 2009
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.0 years ago

Interventions

Etanerceptdrug

Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks

Etanercept + Acitretindrug

Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks

Acitretindrug

Acitretin at a dose of 10mg BID for 24 weeks